Cargando…

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horiuchi, Dai, Kusdra, Leonard, Huskey, Noelle E., Chandriani, Sanjay, Lenburg, Marc E., Gonzalez-Angulo, Ana Maria, Creasman, Katelyn J., Bazarov, Alexey V., Smyth, James W., Davis, Sarah E., Yaswen, Paul, Mills, Gordon B., Esserman, Laura J., Goga, Andrei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328367/ https://www.ncbi.nlm.nih.gov/pubmed/22430491 http://dx.doi.org/10.1084/jem.20111512

Ejemplares similares

CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation
por: Huskey, Noelle E., et al.
Publicado: (2015)

Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors
por: Bazarov, Alexey V, et al.
Publicado: (2011)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

BORIS (CTCFL) Is Not Expressed in Most Human Breast Cell Lines and High Grade Breast Carcinomas
por: Hines, William C., et al.
Publicado: (2010)

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28
por: Zimmermann, Christine, et al.
Publicado: (2017)

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
por: Zhang, Tingting, et al.
Publicado: (2020)

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
por: Borankova, Karolina, et al.
Publicado: (2023)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
por: Houles, Thibault, et al.
Publicado: (2022)

CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
por: Sang, Xiaoye, et al.
Publicado: (2022)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
por: Sun, Zhe, et al.
Publicado: (2022)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
por: Tang, Lin, et al.
Publicado: (2020)

Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines
por: Okada, Yoshinari, et al.
Publicado: (2017)

In vivo Reprogramming of Cancer Metabolism by MYC
por: Camarda, Roman, et al.
Publicado: (2017)

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
por: Camarda, Roman, et al.
Publicado: (2016)

Promotion of variant human mammary epithelial cell outgrowth by ionizing radiation: an agent-based model supported by in vitro studies
por: Mukhopadhyay, Rituparna, et al.
Publicado: (2010)

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening
por: Zhou, Zongxiang, et al.
Publicado: (2014)

Genetic screening for anticancer genes highlights FBLN5 as a synthetic lethal partner of MYC
por: Masood, Motasim, et al.
Publicado: (2023)

Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer
por: Jian, Yunting, et al.
Publicado: (2021)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Cdk2: a key regulator of the senescence control function of Myc
por: Hydbring, Per, et al.
Publicado: (2010)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
por: Brägelmann, Johannes, et al.
Publicado: (2017)

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Xue, Yibo, et al.
Publicado: (2019)

A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors
por: Xu, Ying, et al.
Publicado: (2022)

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
por: Huang, Chun-Hao, et al.
Publicado: (2014)

MYC Modulation around the CDK2/p27/SKP2 Axis
por: Hydbring, Per, et al.
Publicado: (2017)

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
por: Pitolli, Consuelo, et al.
Publicado: (2023)

Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer
por: Brisard, Daphne, et al.
Publicado: (2018)

Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality
por: Szmyd, Radoslaw, et al.
Publicado: (2018)

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
por: Chandriani, Sanjay, et al.
Publicado: (2009)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7v7t5h49rhfg6k8g94f1e7e5sc